Novo Nordisk is organised under Danish law as a public limited liability company.
Novo Nordisk’s share capital is divided into A shares and B shares.
Novo Nordisk’s share capital is DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.
Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each B share of DKK 0.2 (the present denomination of the company's shares) carries 20 votes and each A share of DKK 0.2 carries 200 votes.
On 2 January 2014 the B shares were split in a five-for-one ratio and the trading unit of the B shares listed on Nasdaq Copenhagen was changed from DKK 1 to DKK 0.2. On 9 January 2014, each of Novo Nordisk’s American Depository Receipts (ADRs) listed on New York Stock Exchange was also split in a five-for-one ratio. Hence, the ratio of B shares to ADRs listed on the New York Stock Exchange remains 1:1.
Special rights attached to A shares include pre-emptive subscription rights in case of an increase of the A share capital, pre-emptive purchase rights in case of a sale of A shares and priority dividend if dividend is below 0.5%. B shares take priority for dividend between 0.5% and 5%, and B shares take priority for liquidation proceedings. However, in practice, A shares and B shares receive the same amount of dividend per share of DKK 0.01.
The Board may issue new shares or buy back shares in accordance with authorisations granted by the general meeting and recorded in the meeting minutes.
In March 2019, the Annual General Meeting approved a reduction of the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of 50,000,000 B shares of DKK 0.20 each from the company's own holdings of B shares at a nominal value of DKK 10,000,000. The reduction of the company's B share capital was implemented on 24 April 2019.
In March 2020, the Annual General Meeting approved a reduction of the company's B share capital from DKK 372,512,800 to DKK 362,512,800 by cancellation of 50,000,000 B shares of DKK 0.20 each from the company's own holdings of B shares at a nominal value of DKK 10,000,000. The reduction of the company's B share capital will be implemented in April 2020.
All A shares are held by Novo Holdings A/S, a Danish private limited liability company fully owned by the Danish self-governing foundation, the Novo Nordisk Foundation. The A shares are not listed but are in principle transferable. However, according to the Articles of Association of the Foundation, the A shares cannot be divested by Novo Holdings A/S or the Foundation.
The B shares are listed on Nasdaq Copenhagen and on the New York Stock Exchange as American Depository Receipts (ADRs) under the symbol NVO, and there are no transferability restrictions on the B shares.
As of 5 November 2019, the A shares held by Novo Holdings A/S represent 22.4% of the total share capital and 74.3% of the total number of votes in the company. In addition, the B shares held by Novo Holdings A/S as of 5 November 2019 represent 5.7% of the total share capital and 1.9% of the total number of votes. Holding 28.1% of the total share capital, Novo Holdings A/S controls 76.1% of the total number of votes. Treasury shares are included in the above, however voting rights of treasury shares cannot be exercised.
Novo Nordisk is not aware of the existence of any agreements between shareholders on the exercise of votes or control.
The stake held by board members and employees cannot be determined exactly. However, Novo Nordisk estimates that as of March 2019, the B-shares held by Novo Nordisk board members and employees represent less than 1.5% of the capital and less than 0.5% of the total number of votes in Novo Nordisk.
Novo Nordisk is of the opinion that the current share and ownership structure of Novo Nordisk serves the interests of the shareholders and the company well as it provides strategic flexibility to pursue Novo Nordisk’s vision and a good balance between long-term shareholder value creation and competitive shareholder return in the short-term.
It is Novo Nordisk’s
opinion that the company's transparent share structure is to the
benefit of its shareholders who know in advance the relative voting
power of each share class.
The current differentiation of voting rights cannot be revoked, as this would violate the Articles of Association of the Foundation, which have been approved by the Danish authorities.